Stockscreener 앱 받기
7.09
3.67%
-0.27
시간 외 거래:
7.36
0.27
+3.81%
전일 마감가:
$7.36
열려 있는:
$7.2
하루 거래량:
107.14K
Relative Volume:
0.89
시가총액:
$52.02M
수익:
$140.46M
순이익/손실:
$-146.34M
주가수익비율:
-5.5827
EPS:
-1.27
순현금흐름:
$-117.73M
1주 성능:
+16.80%
1개월 성능:
+83.68%
6개월 성능:
-44.11%
1년 성능:
-58.17%
1일 변동 폭
$7.04
$7.83
1주일 범위
$5.94
$7.8969
52주 변동 폭
$3.51
$18.00
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
명칭
Karyopharm Therapeutics Inc
전화
617-658-0600
주소
85 WELLS AVENUE, NEWTON, MA
KPTI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
7.09 | 52.02M | 140.46M | -146.34M | -117.73M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-01-19 | 개시 | Piper Sandler | Overweight |
| 2022-11-04 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-11-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-08-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-08-06 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | 개시 | Morgan Stanley | Overweight |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-07-23 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-07-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-05 | 재확인 | Robert W. Baird | Outperform |
| 2019-03-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-02-28 | 재확인 | BofA/Merrill | Underperform |
| 2019-02-27 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | 개시 | B. Riley FBR | Buy |
| 2018-11-09 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2018-05-24 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-04-02 | 재개 | Leerink Partners | Outperform |
| 2017-11-15 | 재개 | H.C. Wainwright | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2016-09-08 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-08-18 | 개시 | H.C. Wainwright | Buy |
| 2016-06-28 | 개시 | Robert W. Baird | Outperform |
모두보기
Karyopharm Therapeutics Inc 주식(KPTI)의 최신 뉴스
Redefining Myelofibrosis Care: Can Karyopharm's Selinexor Lead The Way? - RTTNews
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Citizen Tribune
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq L - GuruFocus
Karyopharm Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Medidata Solutions, Inc. Announces Expanded Partnership with Karyopharm Therapeutics - marketscreener.com
Triple Refractory Multiple Myeloma Therapeutics Market Size - openPR.com
Karyopharm therapeutics CEO Richard Paulson sells $916 in stock By Investing.com - Investing.com South Africa
Karyopharm therapeutics CEO Richard Paulson sells $916 in stock - Investing.com
Karyopharm Therapeutics (NASDAQ:KPTI) Shares Pass Below Two Hundred Day Moving Average – Time to Sell? - Defense World
KPTI stock touches 52-week low at $5.55 amid market challenges - Investing.com
Piper Sandler cuts Karyopharm stock target to $15 from $75 - Investing.com
Piper Sandler cuts Karyopharm stock target to $15 from $75 By Investing.com - Investing.com South Africa
Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below 200-Day Moving Average – Time to Sell? - Defense World
Karyopharm therapeutics SVP sells $17,567 in shares By Investing.com - Investing.com Canada
Karyopharm therapeutics CEO Richard Paulson sells $73,555 in stock By Investing.com - Investing.com South Africa
Karyopharm Therapeutics Executives Sell Shares - TradingView
Karyopharm therapeutics CEO Richard Paulson sells $73,555 in stock - Investing.com
Karyopharm therapeutics SVP sells $17,567 in shares - Investing.com India
Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Lowered to $54.00 at Robert W. Baird - Defense World
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm - ACCESS Newswire
Karyopharm Therapeutics Inc. (KPTI), Mallinckrodt plc (MNK) & National General Holdings Corp. (NGHC)Bronstein, Gewirtz & Grossman, LLCClass Action Reminder - ACCESS Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MENAFN.COM
KPTI Stock Touches 52-Week Low at $7.58 Amid Market Challenges - Investing.com
Karyopharm Therapeutics (KPTI) Projected to Post Earnings on Thursday - MarketBeat
International Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month - GlobeNewswire Inc.
Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Raised to $56.00 - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Karyopharm Therapeutics (NASDAQ:KPTI) Stock - MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Down 93.1% in February - MarketBeat
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Down 9%What's Next? - MarketBeat
Karyopharm Therapeutics (NASDAQ:KPTI) Sees Large Volume Increase After Analyst Upgrade - MarketBeat
HC Wainwright Issues Optimistic Estimate for KPTI Earnings - MarketBeat
FY2025 Earnings Estimate for KPTI Issued By Leerink Partnrs - MarketBeat
Karyopharm Therapeutics (KPTI) to Release Quarterly Earnings on Thursday - Defense World
Karyopharm Therapeutics Inc.’s SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com India
Karyopharm Therapeutics Inc.’s SWOT analysis: biotech firm’s stock faces pivotal year By Investing.com - Investing.com South Africa
Research Analysts Issue Forecasts for KPTI Q1 Earnings - MarketBeat
Royal Bank of Canada Reaffirms Outperform Rating for Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat
Karyopharm announces 1-for-15 reverse stock split - MSN
Karyopharm enacts 1-for-15 reverse stock split to boost price - Investing.com Australia
Karyopharm enacts reverse stock split to meet Nasdaq standards By Investing.com - Investing.com South Africa
Karyopharm enacts reverse stock split to meet Nasdaq standards - Investing.com
Karyopharm Unveils 1-for-15 Reverse Stock Split, Effective February 25, 2025 - Nasdaq
Karyopharm Therapeutics to Implement 1-for-15 Reverse Stock Split -February 24, 2025 at 01:18 pm EST - Marketscreener.com
Karyopharm Therapeutics Inc (KPTI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):